Key Takeaways
Bayer’s fourth-quarter sales fell by over 1% on the same quarter of 2023 while its stock price rose by up to 6% on the announcement.
The prospects for its new drug launches in 2025 likely contributed to investors’ warm reception although its full-year 2025 revenue guidance was for a modest decline.
Having limped away wounded from a failed study of its experimental anticoagulant asundexian in 2023, Bayer has another chance to redeem itself in 2025.
Of all the stock price reactions in the fourth-quarter 2024 earnings season, the last – that of Bayer – was...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?